Rentschler Biotechnologie GmbH has opened a U.S.-based sales office in New Providence, NJ. Rentschler, a full-service biopharmaceutical CMO, is expanding its sales activities in an effort to improve the support for its North American clients. Its manufacturing and fill/finish services are carried out at the company’s facilities in Laupheim, Germany, in accordance with international GxP standards.

Rentschler is currently expanding the capacities of its technological and operative plants, allowing the production of material for supplying both clinical studies and the market. Also, setting up additional fermenter suites has strengthened the company’s biotechnology business of custom manufacturing services from cell line development to large-scale cGMP production, registration of drugs and fill/finish, according to a company statement.

Dr. Nikolaus F. Rentschler, chief executive officer at Rentschler Biotechnologie, commented, “We have completed a number of successful projects with clients in the U.S. With the U.S. sales office we want to further develop our North American business.”